A systematic review and meta-analysis reported that plasma GFAP levels distinguished between patients with AD and individuals with cognitively normal function, and were strongly associated with brain Aβ pathology; these observations led to speculations for GFAP as a potential blood biomarker for AD [10]. The gene discussed is GFAP; the disease is Alzheimer disease.